On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) CEO Discusses New Subsidiaries, Intellectual Property in Interview on Uptick Newswire’s Stock Day Podcast

Company: Lexaria Bioscience Corp. (LXRP)
Category: News

Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a drug delivery platform innovator that has developed and out-licenses its disruptive delivery technology, was recently featured on Uptick Newswire’s Stock Day Podcast. Chairman of the Board and CEO Chris Bunka provided an update regarding Lexaria’s licenses and technology. “Lexaria has been somewhat of a pioneer in this aspect of the business. We have been beating the drum on intellectual property since we began in 2014,” Bunka stated in the interview. “We now have over 50 patents outstanding in over 40 countries around the world. Our IP suite is one of the biggest and strongest in the industry.” Bunka also discussed the company’s four new subsidiaries with specific focuses on pharmaceutical, hemp, nicotine and cannabis. “Each one of our subsidiary companies has been empowered through exclusive licensing arraignments with our parent company to be able to offer our broad intellectual property suite to their respective customers,” Lexaria Chairman of the Board and CEO Chris Bunka stated in the interview.

To listen to the full interview, visit http://nnw.fm/4kZK6

To view the full press release, visit http://nnw.fm/U6bzI

About Lexaria Bioscience Corp.

Lexaria Bioscience Corp. licenses disruptive patented delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the USA and in Australia for utilization of its DehydraTECH™ delivery technology. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information, visit the company’s website at www.LexariaBioscience.com.

More from NetworkNewsBreaks

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 212.418.1217